Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value
-
Shares outstanding
-
49,883,741
-
Total 13F shares
-
2,345,581
-
Share change
-
+174,391
-
Total reported value
-
$11,751,749
-
Price per share
-
$5.01
-
Number of holders
-
27
-
Value change
-
+$904,285
-
Number of buys
-
8
-
Number of sells
-
15
Institutional Holders of TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) as of Q4 2024
As of 31 Dec 2024,
TriSalus Life Sciences, Inc. - Common stock, $0.0001 par value (TLSI) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,345,581 shares.
The largest 10 holders included
Wealthcare Advisory Partners LLC, VANGUARD GROUP INC, Duquesne Family Office LLC, GEODE CAPITAL MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, MILLENNIUM MANAGEMENT LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, MSD Partners, L.P., NORTHERN TRUST CORP, and BlackRock, Inc..
This page lists
28
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.